INTRODUCTION

Gliomas are known as the most common malignant tumours of the central nervous system (CNS) and express aggressive and malignant progression and high rates of recurrence. Even though the traditional treatment methods (including surgical resection, radiotherapy and chemotherapy) have made considerable progress, the survival rate of glioma remains at a low level. A better understanding of glioma that provides a new potential treatment to glioma needs a breakthrough.

Tumour cells have multiple mechanisms for evading cell death through radiation therapy. These mechanisms include the ability of cancer cells to repair DNA damage caused by radiation and changes in the tumour microenvironment, such as hypoxia, elevated cytokine levels and transition of epithelial cells to mesenchymal cells. Hypoxia is a state of depriving tissues of enough oxygen supply and a common microenvironmental feature of almost all solid tumours. Hypoxia is also a pathophysiological status, usually due to the rapid proliferation of cancer cells beyond their blood supply, thus depleting nutrients and available oxygen. The hypoxic microenvironment has caused a great obstacle to the clinical effect of radiotherapy, because hypoxic tumours need three times the normal radiotherapy dose to achieve the cell death effect required by normal oxygen tumours. Glioma cell can adapt to hypoxic environment through various mechanisms, and hypoxia enhances glioma cell radiotherapy resistance, drug resistance and invasion ability. Hypoxia-inducible factors in glioma cells are involved in this process.

HAX1 maintains the glioma progression in hypoxia through promoting mitochondrial fission

Jinghui Lin | Yang Wang | Zhiqing Lin

Department of Neurosurgery, Ningbo First Hospital, Ningbo, China

Correspondence
Zhiqing Lin, Department of Neurosurgery, Ningbo First Hospital, No. 59, Liuting Street, Ningbo 315000, China.
Email: 13805884195@139.com

Funding information
Chinese Medicine Research Program of Zhejiang Province, Grant/Award Number: 2021ZA129

Abstract
HCLS1-associated protein X-1 (HAX1), an anti-apoptotic molecular, overexpresses in glioma. However, the role of HAX1 in glioma cell surviving in hypoxic environment remains unclear. Western blotting, qRT-PCR, Transwell assay, TUNEL assay, wound-healing assay, clone formation, tumour xenograft model and immunohistochemical staining were used to investigate the role of HAX1 in glioma. HAX1 regulated by HIF-1α was increased in glioma cells cultured in hypoxia. Silencing of HAX1 could cause an increased apoptosis of glioma cells cultured in hypoxia. Silencing of HAX1 also decreased the proliferation, migration and invasion of glioma cells cultured in hypoxia. Increased mitochondrial fission could prevent glioma cells from the damage induced by HAX1 knockdown in hypoxia. Furthermore, HAX1 was found to regulate glioma cells through phosphorylated AKT/Drp signal pathway. In conclusion, our study suggested that HAX1 promoted survival of glioma cells in hypoxic environment via AKT/Drp signal pathway. Our study also provided a potential therapeutic target for glioma.

KEYWORDS
glioma, HCLS1-associated protein X-1, hypoxia, mitochondrial fission
factor 1α (HIF-1α) facilitates the survival, invasion and proliferation of glioma by the release of DLK1 intracellular fragments and nuclear translocation.13 HIF-1α also improves epithelia mesenchymal transition and chemoresistance of glioma through inducing ferritin light chain (FTL).14 Many molecules also regulate the characteristics of glioma in a hypoxic environment by HIF-1α. For example, IncRNA H19 enhances glioma angiogenesis through HIF-1α.15 Exosomes containing linc01060 can improve the progression of glioma by regulating MZF1/c-Myc/HIF-1α signalling pathway.16 ELTD1 promotes glioma proliferation, migration and invasion by stimulating JAK/STAT3/HIF-1α signalling pathway.17 However, the mechanism of glioma in a hypoxic environment is still not fully understood.

HS-1-associated protein X-1 (HAX1) was firstly reported as a protein to interact with HS-1 20 years ago.18 HAX-1 is a 35 kDa protein related to the cytoplasmic surface of mitochondria and endoplasmic reticulum (ER) membranes, but lacks appropriate transmembrane domains.19 Like HS1, HAX-1 is a multifunctional protein that interacts with cytoplasmic surface proteins in the mitochondria. Through these interactions, HAX-1 is thought to regulate mitochondrial membrane potential, seems to regulate calcium signalling.20 HAX1 regulates multiple pathophysiological processes and cellular metabolism, such as apoptosis, mitochondrial function, calcium homeostasis and cell migration.20,21 The preliminary characterization of HAX1 reports the existence of the Bcl2 homology (BH) module, which is a protein motif found in the Bcl2 family of apoptosis regulatory proteins. HAX1 can promote the survival and metastasis of NSCLC by AKT/mTOR and MDM/P53 signalling pathway.22 Decreased expression of KDM4B induces mitochondrial apoptosis by reducing HAX1 expression in colorectal cancer.23 HAX1 also represses apoptosis in prostate cancer through inhibiting caspase-9 activation.24 Importantly, recent studies reported that HAX1 was overexpressed in glioma and inhibits apoptosis of glioma.25-27 However, the role of HAX1 in glioma cell cultured in hypoxia remains unclear.

Mitochondria are also highly dynamic organelles that adapt to stress through various means. For example, mitochondria have a proteolytic system to degrade their misfolded proteins. Damaged mitochondrial outer membrane proteins can be degraded by the proteasome or eliminated by mitochondrial autophagy. Mitochondria maintain structural and functional integrity through continuous fusion and fission.28,29 Therefore, mitochondrial fission is very important for the integrity of mitochondria. The promotion of mitochondrial fission can enhance tumour malignancy of cancer cells.30-34 Induced mitochondrial fission improves human lung cancer stem cell stemness by mitophagy.33 Meanwhile, promotion of mitochondrial fission is essential for Liver Cancer-Initiating cell maintenance.35 Promotion of XBPI-MARCH5-MFN2 axis can inhibit mitochondrial fission and mitophagy to be against Melanoma cells.34 Drp-1, a regulatory molecule of mitochondrial fission, was silenced to reduce the biological malignancy of glioma stem cells.30 What is more, inhibition of mitochondrial fission can enhance the effect of interference with NDUFA4L2 on glioma cells.35

In this study, we found that HAX1 was upregulated in glioma cell cultured in hypoxia. HIF-1α could increase the expression of HAX1 to protect glioma cell in hypoxia. Silencing of HAX1 was also able to induce mitochondrial fission due to the damage of mitochondrial function, while induction of mitochondrial fission could restrain the effect of HAX1 knockdown on glioma cell cultured in hypoxia.

2 | METHODS AND MATERIALS

2.1 | Cell culture

Glioma cell lines T98G, U87 and U251 were obtained from Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All experimental protocols were approved by the Human Ethics Committee of Ningbo First Hospital (Ningbo, China). U87 were cultured in MEM medium (Gibco) containing 1%NEAA (Gibco), 10% FBS (Gibco), 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco). T98G and U251 were cultured in DMEM high-glucose medium (Gibco) containing 1%NEAA (Gibco), 10% FBS (Gibco), 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco). Cells were cultured at 37°C in a humidified atmosphere of 5% CO₂, 95% air and 100% humidity or in hypoxic environments (1% O₂).

2.2 | RNA interference and vectors

Three small interference RNA to HAX1, HIF-1α and HIF-2α was established by GenePharma, China. The Lentivirus vector containing short hairpin RNAs (shRNA) knock-down HAX1 (sh-HAX1), Lentivirus knock-down Negative Control (sh-NC), lentivirus over-express HAX1, Lentivirus over-express Negative Control were designed and synthesized from Genome ditech (Shanghai, China). The sequences of HAX1, HIF-1α and HIF-2α were as follows: si-HAX1: Sense: 5'-GGAUACGUUUUCCACGAUAAdTdT-3', Antisense: 5'-UUUAUCUGUGAAACGUAUCCdTdT-3'; si-HAX1-1: Sense: 5'-GAGUGAUGCAAGAAGUGAAUUU-3', Antisense: 5'-UUCACUUUCUGCAUCUCUUU-3'; si-HAX1-3: Sense: 5'-GAAUGUCGCUGAUAGCdTdT-3', Antisense: 5'-CACGUAGGCGC-3'. The doses HAX1 and HIF-1α used were 50 nM according to manufacturer’s protocol. The virus titre of lenti-HAX1 and control virus are 1 × 10⁸ IU/ml. The medium was 2 ml, and the final concentration of virus was 1 × 10⁸ TU/ml.

2.3 | RNA extraction and qRT-PCR

Cells were lysed and total RNA was extracted using Trizol reagent (Beyotime, China) in accordance with manufacture’s protocol. The cDNA was synthesized by reverse transcription kit (TaKaRa).

LIN ET AL.
according to manufacturer's protocol. QRT-PCR was carried out with one-step RT qPCR SYBR Green Kit (DBI). The primers were purchased from Sangon Biotech and the sequences used were listed as follow:

HAX1-Forward: ACGCCTGCTCAATTCTCA, HAX1-Reverse: AAGCCAAATTCCTCAGGGG;
HIF-1α-Forward: 5′-AGTGTACCCTAACTAGCCG-3′, HIF-1α-Reverse: 5′-CACAAATCAGCACCAAGC-3′. 2−ΔΔCT methods were applied to calculate the mRNA expression levels.

2.4 | Western blotting

Electrophoresis was performed by SDS-PAGE gel and electro-transfer was performed by a trans-blot transfer slot (Bio-Rad). PVDF membrane (Bio-Rad) was blocked by 5% skimmed milk for 2 h at room temperature. The primary antibodies were added to membrane in accordance with protocols and incubated at 4°C for 12 h. The primary antibodies include β-actin (Beyotime, 1:1000), HAX1 (Proteintech, 1:1000), HIF-1α (Proteintech, 1:1000), Drp1 (Proteintech, 1:1000), AKT (CST, 1:1000), p-AKT (CST, 1:100) and p-Drp1 (CST, 1:1000). Membranes were washed three times with TBST, and secondary antibodies (Proteintech, 1:1000) were added and incubated at room temperature for 1 h. ECL reagent (Millipore) was used to perform chemiluminescence detection.

2.5 | TUNEL assay

Cells were seeded on the coverslips. 4% paraformaldehyde was used to fix cells and 0.3% Triton X-100 was used to penetrate cells for 5 min. 50 μL TUNEL reagent was added to coverslip and incubated for 1 h. Images were taken by microscopy (Olympus BX51).

2.6 | Transwell assay

Transwell chamber and Matrigel were gained from Corning (USA). The lower chamber was added with 500 μl culture medium containing 10% serum, and serum-free medium containing 5 × 10^4 cells was added into the upper chamber and cultured for 24 h in hypoxic environments (1% O_2). The invasion rate was counted after the invaded cells were stained with 0.1% crystal violet (Sinopharm Chemical Reagent).

2.7 | Wounding healing assay

Cells were seeded into 6 cm plate overnight in a consistent and humidified atmosphere of 5% CO_2 at 37°C. A vertical scratching was made by the tip of the pipette and cells were incubated in medium containing 1% serum for 24 h. The relative migration distance of cells was evaluated by a Leica DMI3000 B inverted microscope.

2.8 | Clone formation

Colone formation was carried out following previously published methods. Briefly, cells during logarithmic phases were added into six-well plates at a density of 1000 cells per well. Two weeks later, we fixed cells by methanol for 30 min. Colonies were then stained by using 0.1% crystal violet (Beyotime), and the relative numbers of colonies were manually calculated.

2.9 | Tumour xenograft model

Five male BALB/C nude mice (18–20 g) purchased from Shanghai SLAC Laboratory Animal Co., Ltd. were subcutaneously injected with U87 cells transfected with Lenti-shNC or Lenti-shHAX1. After 1 month, mice were sacrificed and tumours were excised. Tumours were weighed and used to perform immunohistochemical assays. The volume of tumour was measured per 5 days. This information was added in the revised manuscript. Tumour sizes were calculated with the formula: (mm^3) = (L × W^2) × 0.5.

2.10 | Immunohistochemical staining

The tumour specimens were fixed with 4% formaldehyde, embedded in paraffin, and cut into 4 μm sections for immunohistochemical analysis. Briefly, 3% hydrogen peroxide was used to block the endogenous peroxidase activity for 10 min, and then, 5% BSA was used to block the non-specific binding sites for 30 min at room temperature. Primary antibodies were incubated overnight at 4°C. For primary antibodies, we used PCNA (1:100, Proteintech), HAX1 (1:150, Proteintech), p-Drp (1:200, Proteintech) and p-AKT (1:200, CST). Sections were incubated with an appropriate HRP-conjugated secondary antibody (Santa Cruz Biotechnology) and counterstained with haematoxylin.

2.11 | Mitochondrial morphology

When the cells were cultured to a certain density in a cell culture plate, remove the cell culture solution, add the Mito-Tracker Red CMXRos (Beyotime) working solution, and incubate at 37°C for 15–30 min. Remove the Mito-Tracker Red CMXRos working solution and add fresh cell culture solution pre-incubated at 37°C. Observe with a fluorescence microscope. At this time, mitochondrial morphology can be observed as bright and intense fluorescent staining.

2.12 | Statistical analysis

SPSS 20.0 statistical software was used to perform statistical analysis. The measurement data are expressed as x ± s. The independent sample t test was used for comparison between the two
groups. One-way analysis of variance (ANOVA) was used for comparison between groups, followed by Tukey multiple comparisons. \( p < 0.05 \) is of systematic significance. \( p < 0.05, ^* p < 0.01, ^{**} p < 0.001 \).

3 | RESULTS

3.1 | Hypoxia induces HAX1 expression in gliomas

To investigate whether hypoxia induces HAX1 expression, glioma cell line T98G, U87 and U251 were cultured in hypoxia for 12, 24 and 48 h. HAX1 mRNA and protein expression were increased remarkably in hypoxia (Figure 1A–E and F). However, the expression of HAX1 is not time dependent in hypoxia. Therefore, follow-up experiments were performed in glioma cells cultured in hypoxia for 24 h. To further confirm the expression of HAX1 in human gliomas, we clarified the expression of HAX1 in human gliomas by TCGA analysis database: http://ualcan.path.uab.edu/index.html. As was shown in Figure 1G–J, HAX1 mRNA expression was higher in gliomas that normal tissue. Gender has no difference in the effect of HAX1 expression in glioma. No difference in race and age. Deng et al. showed the same results that HAX1 expression was increased in glioma tissues.\(^{25}\) These results showed that HAX1 expression was overexpression in gliomas and hypoxia could induce HAX1 expression in glioma cell lines.

3.2 | HAX1 knockdown inhibits the proliferation, invasion and migration of glioma cell as well as cause apoptosis of glioma cells

To further determine the role of HAX1 in glioma cell cultured in hypoxia, we designed small interference RNA (si-RNA) to silence the expression of HAX1. The effect of si-HAX1 on glioma cell was confirmed by qRT-PCR and Western blotting. As was shown in Figure 2A,B, HAX1 mRNA expression was reduced by si-HAX1-1, si-HAX-2 and si-HAX-3 in T98G and U251 cells cultured in hypoxia (T98G/HY and U251 HY). HAX1 protein expression also was decreased by si-HAX1-1, si-HAX-2 and si-HAX-3 in T98G/HY and U251/HY cells. Si-HAX1-1 was used in follow-up experiments. In subsequent experiment, silence of HAX1 was able to induce T98G/HY and U251/HY cell apoptosis (Figure 2C). As an anti-apoptotic protein, silence of HAX1 caused T98G/HY and U251/HY cell apoptosis, which was consistent with early discovery.\(^{22,24,39,40}\) In addition, silencing of HAX1 also caused a decreased invasion, proliferation and migration of T98G/HY and U251/HY cells (Figure 2D–F). These results demonstrated that HAX1 knockdown could reduce the proliferation, invasion and migration of glioma cells cultured in hypoxia. HAX1 knockdown also promoted the apoptosis of glioma cells in hypoxia.

3.4 | HAX1 acts as a downstream of HIF-1α in glioma cell in hypoxia

HIF-1α (hypoxia-inducible factor 1 subunit α) can improve the survival ability and characteristics of various types of tumour cells or organs in a hypoxic environment.\(^{38,41-44}\) Therefore, we speculated that HAX1 served as downstream of HIF-1α to regulate glioma cell in hypoxia. To confirm our hypothesis, si-HIF-1α was designed to silence HIF-1α expression. The results of qRT-PCR showed that HIF-1α mRNA was reduced by si-HIF-1α (Figure 3A). HIF-1α knockdown also caused a decreased mRNA expression of HAX1 (Figure 3B). Then, Western blotting was performed to detect the protein expression of HIF-1α and HAX1. HIF-1α protein expression was reduced significantly in T98G/HY and U87/HY cells transfected with si-HIF-1α (Figure 3C). The decreased HAX1 protein expression was also caused by si-HIF-1α (Figure 3C). CHIP experiments had been performed and the results showed that HIF-1α upregulated the expression of HAX1 by interacting to the HAX1 promoter (Figure 3D). To confirm whether HIF-2α was involved in regulating HAX1 expression, HIF-2α was silenced by si-HIF-2α. The results showed that HIF-2α did not affect the regulation of HAX1 (Figure 3E). Immunofluorescence results showed that HIF-1α knockdown could inhibit the HAX1 protein expression (Figure 3F). These results indicated that HAX1 acted as a downstream of HIF-1α to maintain the survival of glioma cell.

3.3 | HIF-1α knockdown reduces HAX1 expression in glioma cell in hypoxia

HIF-1α knockdown could inhibit the HAX1 expression in glioma cell in hypoxia. To further investigate whether HAX1 serves as a downstream of HIF-1α to maintain the survival ability and characteristics of glioma, we established LV3-pGLV-H1 + Puro plasmids with pcDNA-HAX1 or control oligonucleotides (Lenti-HAX1 and Lenti-NC) to overexpress HAX1 protein expression. As was shown in Figure 4A and B, Lenti-HAX1 was able to upregulate HAX1 expression in T98G/HY cells. HIF-1α knockdown caused T98G/HY cell apoptosis while overexpression of HAX1 was capable of reducing T98G/HY cell apoptosis transfected with si-HIF-1α (Figure 4C). Subsequently, we found HIF-1α knockdown also decreased the proliferation of T98G/HY cells by Clone formation assay (Figure 4D). HAX1 upregulation could improve mildly the clone formation of T98G/HY cells and promote significantly the clone formation of T98G/HY cells transfected with si-HIF-1α (Figure 4C). HAX1 overexpression could also slightly promote the invasion of T98G/HY cells and relieve si-HIF-1α-induced inhibition of invasion (Figure 4E). For the migration of T98G/HY cells, HAX1 overexpression could only alleviate the effect of si-HIF-1α on T98G/HY (Figure 4F). These results demonstrated that HAX1 acted as a downstream of HIF-1α in glioma cell in hypoxia.
3.5 HAX1 knockdown decreases mitochondrial fission of glioma cells cultured in hypoxia

Mitochondrial fission is a double-edged sword that can protect and damage cells. Previous studies have reported that mitochondrial fission can protect hepatocellular carcinoma cell from hypoxia and promote cisplatin resistance of ovarian cancer. However, mitochondrial fission can repress breast cancer stem cell activity and cause annulus fibrosus cell and nucleus pulposus apoptosis. HAX1 is highly expressed in mitochondria, regulates mitochondrial metabolism and apoptosis induced by mitochondrial pathways. Mito tracker assays showed that...
Silencing of HAX1 decreased significantly mitochondrial fission (Figure 5A). Silencing of HAX1 also decreased the protein level of p-Drp1 in U251/HY cells (Figure 5B). To further confirm the role of mitochondrial fission, we used the mitochondrial fission inhibitor Midivi-1 to treat U251/HY cells transfected with Lenti-NC or Lenti-HAX1. As was shown in Figure 5C,G, Midivi-1 could reduce the invasion of U251/HY cells transfected with Lenti-NC and the protective effect of Lenti-HAX1 in the invasion of U251/HY cells. Inhibition of mitochondrial fission by Midivi-1 was also able to decrease further the proliferation and migration of U251/HY cells (Figure 5D,F,H,J). The reduction of U251/HY cell apoptosis caused by si-HIF-1α also was inhibited by Midivi-1 (Figure 5E,I).
results confirmed that mitochondrial fission induced by HAX1 could protect U251 cells cultured in hypoxia.

3.6 | HAX1 can protect glioma cells through AKT/Drp signal pathway in hypoxia

HAX1 can promote the survival and metastasis of NSCLC by AKT/mTOR and MDM/P53 signalling pathway. To further investigate whether HAX1 enhances the mitochondrial fission by AKT/Drp signal pathway, we detected the protein level of p-AKT after HAX1 knockdown and found that HAX1 knockdown reduced the level of p-AKT in glioma cells (Figure 6A). And then, we used p-AKT agonist SC-79 (5 µg/ml for 1 h) to treat glioma cells after HAX1 knockdown. SC-79 did not change HAX1 expression in U251/HY cells transfected with si-NC or si-HAX1 (Figure 6B). Secondly, Transwell assays, wounding healing assays and TUNEL assays were used to investigate the invasion, migration and apoptosis of U251/
HY cells transfected with si-NC or si-HAX1. SC-79 increased obviously the invasion of U251/HY cells transfected with si-HAX1 (Figure 6C,F). SC-79 increased the migration of U251/HY cells transfected with si-HAX1 or si-NC (Figure 6E,H). On the contrary, SC-79 reduced significantly the apoptosis of U251/HY cells induced by si-HAX1 (Figure 6D,G). These results indicated that HAX-1 promoted the mitochondrial fission via AKT/Drp signal pathway on U251/HY cells.
3.7 | HAX1 knockdown represses glioma growth in vivo

HAX1 function in vivo was evaluated in BALB/c nude mice xenografted with U87 cells. U87/HY cells were transfected with Lenti-shNC or Lenti-shHAX1. The growth of glioma tumour was slower after HAX1 knockdown (Figure 1A). Tumour weight also was reduced by HAX1 knockdown (Figure 7B). HAX1 knockdown significantly reduced tumour volume of glioma tumour (Figure 7C). HAX1 protein expression was decreased by Lenti-shHAX1 in U87/HY cells (Figure 7D).

Moreover, the protein levels of p-Drp and p-AKT were also decreased in Lenti-shHAX1 groups (Figure 7D). The results of immunohistochemical
staining confirmed that HAX1, p-Drp and p-AKT protein levels were reduced in the tissues after HAX1 knockdown (Figure 7E). There was a decrease of PCNA expression in Lenti-shHAX1 groups which indicated HAX1 knockdown inhibited the tumour growth (Figure 7F). These results revealed that HAX1 knockdown induced the inhibition of growth of glioma tumours.

### 4 | DISCUSSION

Glioma is the most common intracranial malignant tumour, which poses a serious threat to human health.\(^5\)\(^2\) According to WHO classification, glioma can be divided into I-V grades, I and II namely low-grade glioma (LGG), III-IV high-grade glioma (HGG). Among them,
glioblastoma multiforme (GBM) has the highest malignant degree. The average survival time of Glioblastoma multiforme (GBM) is only about 1 year. Some studies have reported that its 5-year survival rate is only 9.8%. At present, surgical resection, postoperative adjuvant radiotherapy, chemotherapy, immunotherapy, photodynamic therapy, electric field therapy and other effective treatment methods for glioma are still the first choice, but the prognosis of patients is still poor. Genome-wide molecular maps have revealed the genetic and epigenetic biological characteristics of different types of gliomas, and their clinical value in the diagnosis, prognosis and treatment of gliomas has attracted widespread attention. Therefore, it is of great significance to find useful molecular markers for clinicians to optimize treatment and improve the therapeutic effect of glioma patients.

HAX1, widely expressed in many human organs, was preferentially located in mitochondria, and a small part in the endoplasmic reticulum and nuclear membrane. The molecular weight of HAX1 is 35 kD, and the whole protein is composed of 279 amino acid residues. Our results demonstrated that higher expression of HAX1 was...
found in glioma cells survived in hypoxia. HAX1 knockdown could cause a decrease of proliferation, migration and invasion of glioma cells cultured in hypoxia. HAX1 also increased apoptosis of glioma cells cultured in hypoxia. HAX1 can promote the survival and metastasis of NSCLC by AKT/mTOR and MDM/P53 signalling pathway. HAX1 also represses apoptosis in prostate cancer through inhibiting caspase-9 activation. Importantly, recent studies reported that HAX1 was overexpressed in glioma and inhibits apoptosis of glioma. These results indicated that HAX1 was able to maintain the survival of glioma cells in hypoxia.

As a key molecule in the regulation of hypoxia, HIF-1α promotes cells to adapt to the hypoxic environment by changing the way of cell energy supply and mitochondrial metabolism. Therefore, we first tested whether HIF-1α regulated the expression of HAX1 in glioma. HIF-1α was discovered to improve the expression of HAX1 in glioma cells cultured in hypoxia. Overexpression of HAX1 could attenuate the phenotypic changes caused by HIF-1α knockdown. These results demonstrated that HAX1 acted as a target of HIF-1α to regulate glioma cells in hypoxia.

HAX1 was preferentially located in mitochondria, which showed that HAX1 knockdown might have an important effect on mitochondria. Therefore, we examined the morphology of mitochondria and found that silencing of HAX1 was capable of inhibiting mitochondrial fission. Decreased expression of phosphorylated Drp caused by HAX1 was found in glioma cells. Inhibition of mitochondrial fission could reduce the effect of HAX1 in glioma cells. The sequences of the N-terminal amino acid residues were similar to those of the Bcl-2 protein family, including two BH domains (BH1, AA40-56; BH2, aa74–89). Previous studies have shown that the anti-apoptotic effect of Bcl-2 is regulated by its phosphorylation. When Bcl-2 is phosphorylated at a partial site of a non-structural ring within the molecule, its anti-apoptotic activity decreases, while the loss of this non-structural ring or the mutation of the phosphorylation site within it will lead to an increase in its anti-apoptotic activity.

Besides, mitochondrial quality control requires mitophagy and mitochondrial fission. Mitochondrial fission can induce mitophagy to inhibit cell apoptosis. Reduced dynamin-related protein 1-related mitophagy was able to induce myocardial apoptosis in the ageing heart. Silencing of NDUFA4L2 causes mitophagy to induce mitochondrial fission in glioma cells. Mitophagy induced by mitochondrial fission can protect glioma cells from apoptosis. Inhibition of mitophagy and mitochondrial fission sensitizes cancer cells to chemotherapy through DNM1L-mediated mitochondrial fission.

In the present study, we did not explore the relationship between mitophagy and mitochondrial fission in glioma cells. In the future, we will investigate the mechanism between mitophagy and mitochondrial fission in glioma cells.

Our research found that HAX1 could indeed affect the phosphorylation level of AKT, and increasing the level of phosphorylated AKT can make up for part of the lack of HAX1. At the same time, increasing the level of phosphorylated AKT could promote the phosphorylation of Drp, thereby increasing mitochondrial fission. Therefore, we speculated that HAX1 also has phosphorylation sites, and the phosphorylation of HAX1 affected the phosphorylation of Drp, thereby affecting mitochondrial fission. Phosphorylated AKT play an intermediary role in the middle. However, the in-depth mechanism of them still needed to be confirmed by another research. Recent studies have reported that HAX1 could protect cancer cell via AKT signal pathway. AKT knockdown could reduce the survival of cancer cells by regulating EGFR. mTOR also acts as a downstream of AKT to regulate cancer cell apoptosis. AKT knockdown could reduce the survival of cancer cells by regulating VEGF. Furthermore, AKT was reported to repress glioma cell apoptosis through various signal pathway.

Deng X, Guo XB and their colleague have demonstrated that HAX1 regulates glioma tumour through impacting glioma cells and endothelial progenitor cells. AKT pathway plays an important role in this process. Our study focuses on the effect of HAX1 on glioma in hypoxic environment. This study provides a new understanding of the mechanism of HAX1 in glioma.
In conclusion, our study demonstrated that HAX1 played an important role in glioma cells in hypoxia. HAX1 promoted glioma cells to adapt to hypoxic environment. HAX1 might increase the phosphorylation of Drp through phosphorylation of AKT to promote mitochondrial fission, so as to better adapt to the hypoxic environment (Figure 8). Our research showed how glioma cells adapted to a hypoxic environment, providing potential targets for the treatment of glioma.

ACKNOWLEDGEMENTS
Our study was supported by Chinese Medicine Research Program of Zhejiang Province (No. 20212A129).

CONFLICT OF INTEREST
All authors declare that there are no conflicts of interest.

AUTHOR CONTRIBUTION
Jinghui Lin: Formal analysis (equal); Investigation (equal); Methodology (equal); Software (equal); Visualization (equal); Writing-original draft (equal); Writing-review & editing (equal). Yang Wang: Formal analysis (equal); Investigation (equal); Methodology (equal); Software (equal); Writing-original draft (equal). Zhiqing Lin: Conceptualization (lead); Data curation (lead); Funding acquisition (lead); Project administration (lead); Writing-original draft (equal); Writing-review & editing (equal).

DATA AVAILABILITY STATEMENT
The data and materials in this current study are available from the corresponding author on reasonable request.

ORCID
Zhiqing Lin https://orcid.org/0000-0003-2152-9969

REFERENCES
1. Chang S, Yim S, Park H. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Exp Mol Med. 2019;51(6):1-17.
2. Ciechomska IA, Gielniewski B, Wojtas B, Kaminska B, Mieczkowski J. EGFR/FOXO3a/BIM signaling pathway determines chemosensitivity of BMP4-differentiated glioma stem cells to temozolomide. Exp Mol Med. 2020;52(8):1326-1340.
3. Lee J, Jo DH, Kim JH, et al. Development of a patient-derived xenograft model of glioblastoma via intravitreal injection in mice. Exp Mol Med. 2019;51(4):1-9.
4. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncology. 2012;14(suppl. 5):v1-v49.
5. Wang X, Chen J-X, Zhou Q, et al. Statistical report of central nervous system tumors histologically diagnosed in the sichuan province of China from 2008 to 2013: a west China glioma center report. Ann Surg Oncol. 2016;23(Suppl 5):946-953.
6. Tang LE, Wei F, Wu Y, et al. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. 2018;37(1):87.
7. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia and cancer. J Mol Med. 2007;85(12):1301-1307.
8. Baumann R, Depping R, Delapierre M, Dunst J. Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale? Expert Rev Anticancer Ther. 2016;16(7):751-758.
9. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393-410.
10. Boyd NH, Tran AN, Bernstoch JD, et al. Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics. 2021;11(2):665-683.
11. Chédeville AL, Madureira PA. The role of hypoxia in glioblastoma radiotherapy resistance. Cancers. 2021;13(3):542.
12. Cook KM, Shen H, McKelvey KJ, Gee HE, Hau E. Targeting glucose metabolism of cancer cells with dichloroacetate to radiosensitize high-grade gliomas. Int J Mol Sci. 2021;22(14):7265.
13. Grassi ES, Pantazopoulou V, Pietras A. Hypoxia-induced release, nuclear translocation, and signaling activity of a DLK1 intracellular fragment in glioma. Oncogene. 2020;39(20):4028-4044.
14. Zhou B, Liu J, Kang R, Klioussky DJ, Kroemer G, Tang D. Ferroptosis is a type of autophagy-dependent cell death. Semin Cancer Biol. 2020;66:89-100.
15. Liu ZZ, Tian YF, Wu H, Ouyang SY, Kuang WL. LncRNA H19 promotes glioma angiogenesis through miR-138/HIF-1α/VEGF axis. Neoplasma. 2020;67(1):111-118.
16. Li J, Liao T, Liu H, et al. Hypoxic glioma stem cell-derived exosomes containing Linc01060 promote progression of glioma by regulating the MZF1/c-Myc/ HIF-1x. Can Res. 2020;81(1):114-128.
17. Li J, Shen J, Wang Z, et al. ELTD1 facilitates glioma proliferation, migration and invasion by activating JAK/STAT3/HIF-1α signaling axis. Sci Rep. 2019;9(1):13904.
18. Suzuki Y, Demoliere C, Kitamura D, Takeshita H, Deuschle U, Watanabe T. HAX-1, a novel intracellular protein, localized on mitochondria, directly associates with H51, a substrate of Srf family tyrosine kinases. J Immunol. 1997;158(6):2736-2744.
19. Jeyaraju DV, Cisbani G, De Brito OM, Koonin EV, Pellegrini L. HAX1 lacks BH modules and is peripherally associated to heavy membranes: implications for Omi/HtrA2 and PARL activity in the regulation of mitochondrial stress and apoptosis. Cell Death Differ. 2009;16(12):1622-1629.
20. Fadel B, Grzybowska E. HAX-1: a multifunctional protein with emerging roles in human disease. Biochem Biophys Acta. 2009;1790(10):1139-1148.
21. Alogaili F, Chinnarasu S, Jaeschke A, Kranias EG, Hui DY. Hepatic HAX-1 inactivation prevents metabolic diseases by enhancing mitochondrial activity and bile salt export. J Biol Chem. 2020;295(14):4631-4646.
22. Liang Z, Zhong Y, Meng L, et al. HAX1 enhances the survival and metastasis of non-small cell lung cancer through the AKT/mTOR and MDM2/p53 signaling pathway. Thoracic Cancer. 2020;11(11):3155-3167.
23. Li H, Yang X, Wang G, et al. KDM4B plays an important role in mitochondrial apoptosis by upregulating HAX1 expression in colorectal cancer. Oncotarget. 2016;7(36):57866-57877.
24. Yan J, Ma C, Cheng J, Li Z, Liu C. HAX-1 inhibits apoptosis in prostate cancer through the suppression of caspase-9 activation. Oncol Rep. 2015;34(5):2776-2781.
25. Deng X, Song L, Wei Y, Guo XB. Analysis of the expression of HAX1 gene in human glioma. Neurosci Lett. 2017;657:189-193.
26. Deng X, Song L, Zhao W, Wei Y, Guo XB. HAX-1 Protects Glioblastoma Cells from Apoptosis through the Akt1 Pathway. Front Cell Neurosci. 2017;11:420.
27. Guo XB, Deng X, Wei Y. Hematopoietic substrate-1-associated protein X-1 regulates the proliferation and apoptosis of endothelial progenitor cells through Akt pathway modulation. Stem Cells. 2018;36(3):406-419.
28. Ni HM, Williams JA, Ding WX. Mitochondrial dynamics and mitochondrial quality control. Redox Biol. 2015;4:6-13.
29. Shi S, Wang L, van der Laan LJW, Pan Q, Verstegen MMA. Mitochondrial dysfunction and oxidative stress in liver transplantation and underlying diseases: new insights and therapeutics. *Transplantation*. 2021;105(11):2362-2373.

30. Zhang L, Cao H, Tao H, Yang J, Gong W, Hu Q. Effect of the interference with DRP1 expression on the biological characteristics of glioma stem cells. *Exp Ther Med*. 2021;22(1):696.

31. Prasad P, Ghosh S, Roy SS. Glutamine deficiency promotes stemness and chemoresistance in tumor cells through DRP1-induced mitochondrial fragmentation. *Cell Mol Life Sci*. 2021;78(10):4821-4845.

32. Liu D, Sun Z, Ye T, et al. The mitochondrial fission factor FIS1 promotes stemness of human lung cancer stem cells via mitophagy. *FEBS Open Biol*. 2021;11(7):1979-2007.

33. Wang H, Yi X, Guo S, et al. The XBP1-MARCH5-MFN2 Axis confers endoplasmic reticulum stress resistance by coordinating mitochondrial fission and mitophagy in melanoma. *J Invest Dermatol*. 2021;S0022-202X(21):01243-01244.

34. Chen Z, Wei X, Wang X, et al. NDUFA4L2 promotes glioblastoma progression, is associated with poor survival, and can be effectively targeted by apatinib. *Cell Death Dis*. 2021;12(4):377.

35. Wu Z, Ai X, Hu H, et al. Hematopoietic-substrate-1 associated protein X-1 (HAX-1) regulates liver cancer cells growth, metastasis, and angiogenesis through Akt. *Cancer Biol Ther*. 2019;20(9):1223-1233.

36. Wu W, Hu Z, Zhao Q, et al. Down-regulation of hypoxia-inducible factor-1α and downstream glucose transporter protein-1 gene by β2-elemene enhances the radiosensitivity of lung adenocarcinoma transplanted tumor. *Onco Targets Ther*. 2020;13:11627-11635.

37. Xu WN, Yang RZ, Zheng HL, Jiang LS, Jiang SD. NDUFA4L2 regulated by HIF-1α promotes metastasis and epithelial-mesenchymal transition of osteosarcoma cells through inhibiting ROS production. *Front Cell Dev Biol*. 2020;8:515051.

38. Balcerak A, Trebinska-Stjryewksa A, Wakula M, et al. HAX1 impact on collective cell migration, cell adhesion, and cell shape is linked to the regulation of actomyosin contractility. *Mol Biol Cell*. 2019;30(25):3024-3036.

39. Feng X, Kwiecinska A, Rossmann E, et al. HAX-1 overexpression in multiple myeloma is associated with poor survival. *Br J Haematol*. 2019;185(1):179-183.

40. Xu WN, Zheng HL, Yang RZ, et al. Mitochondrial NDUFA4L2 attenuates the apoptosis of nucleus pulposus cells induced by oxidative stress via the inhibition of mitophagy. *Exp Mol Med*. 2019;51(1):1-16.

41. Yang N, Wang T, Li Q, et al. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α. *J Cell Physiol*. 2021;236(5):3863-3880.

42. Wu Z, Zuo M, Zeng L, et al. OMA1 reprograms metabolism under hypoxia and targets endoplasmic reticulum stress resistance by coordinating mitophagy in melanoma. *EMBO Rep*. 2022;22(1):e105827.

43. Xu WN, Zheng HL, Yang RZ, Jiang LS, Jiang SD. HIF-1α Regulates glucocorticoid-induced osteoporosis through PDK1/AKT/mTOR signaling pathway. *Front Endocrinol*. 2019;10:922.

44. Wu W, Jing D, Huang X, Yang W, Shao Z. Drp1-mediated mitochondrial fission is involved in oxidized low-density lipoprotein-induced AF cell poptosis. *J Orthop Res*. 2021;39(7):1496-1504.

45. Kang L, Liu S, Li J, Tian Y, Yue Y, Liu X. The mitochondria-targeted anti-oxidant MitoQ protects against intervertebral disc degeneration by ameliorating mitochondrial dysfunction and redox imbalance. *Cell Prolif*. 2020;53(3):e12779.

46. Han Y, Kim B, Cho U, et al. Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells. *Oncogene*. 2019;38(45):7089-7105.

47. Lin X-H, Qiu B-Q, Ma M, et al. Suppressing DRP1-mediated mitochondrial fission and mitophagy increases mitochondrial apoptosis of hepatocellular carcinoma cells in the setting of hypoxia. *Oncogenesis*. 2020;9(7):67.

48. Sánchez-Alvarez R, De Francesco EM, Fiorillo M, Sotgia F, Lisanti MP. Mitochondrial fission factor (MFF) inhibits mitochondrial metabolism and reduces breast cancer stem cell (CSC) activity. *Front Oncol*. 2020;10:1776.

49. Simmen T. Hax-1: a regulator of calcium signaling and apoptosis progression with multiple roles in human disease. *Exp Opin Ther Targets*. 2011;15(6):741-751.

50. Shi Y, Li Q, Sun F, et al. Lamprey PHB2 maintains mitochondrial stability by tanslocation to the mitochondria under oxidative stress. *Fish Shellfish Immunol*. 2020;104:613-621.

51. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394-424.

52. Wirth T, Samaranayake H, Pikkarainen J, Määttä AM, Ylä-Herttuala S. Clinical trials for glioblastoma multiforme using adenviral vectors. *Curr Opin Mol Ther*. 2009;11(5):485-492.

53. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol*. 2009;10(5):459-466.

54. Diamandis P, Aldape KD. Insights from molecular profiling of adult glioma. *J Clin Oncol*. 2017;35(21):2386-2393.

55. Lees DM, Hart IR, Marshall JF. Existence of multiple isoforms of H51-associated protein X-1 in murine and human tissues. *J Mol Biol*. 2008;379(4):645-655.

56. Kim I, Kim M, Park MK, et al. The disubstituted adamantyl derivative LW1564 inhibits the growth of cancer cells by targeting mitochondrial respiration and reducing hypoxia-inducible factor (HIF)-1α accumulation. *Exp Mol Med*. 2020;52(11):1845-1856.

57. Islam SMT, Won J, Khan M, Mannie MD, Singh I. Hypoxia-inducible factor-1 drives divergent immunomodulatory functions in the pathogenesis of autoimmune diseases. *Immunology*. 2021;164(1):31-42.

58. Li B, Hu Q, Xu R, et al. Hax-1 is rapidly degraded by the proteasome dependent on its PEST sequence. *MColl Cell Biol*. 2012;13:20.

59. Chang BS, Minn AJ, Muchmore SW, Fesik SW, Thompson CB. Identification of a novel regulatory domain in Bcl-x(L) and Bcl-2. *EMBO J*. 1997;16(5):968-977.

60. Haldar S, Basu A, Croce CM, Serino-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. *Can Res*. 1998;58(8):1609-1615.

61. Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. *Proc Natl Acad Sci USA*. 1999;96(7):3775-3780.

62. Wei X, Wu YE, Wang W, Zhang S, Liu D, Liu H. Decreased dynamin-related protein 1-related mitophagy induces myocadial apoptosis in the aging heart. *Acta Biochim Biophys Sin* 2021;53(10): 1354-1366.

63. Zhou J, Li G, Zheng YI, et al. A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapu- ty through DNM1L-mediated mitochondrial fission. *Autophagy*. 2015;11(8):1259-1279.

64. Qiu W, Schönlöben F, Li X, et al. PIK3CA mutations in head and neck squamous cell carcinoma. *Clin Cancer Res*. 2006;12(5):1441-1446.

65. Roudsari NM, Lashgari N-A, Momtaz S, et al. Inhibitors of the PI3K/AKT/mTOR pathway in prostate cancer chemoprevention and intervention. *Pharmaceutics*. 2021;13(8):1195.

66. Rasmussen N, Rathmell WK. Looking beyond inhibition of VEGF/ mTOR: emerging targets for renal cell carcinoma drug development. *Curr Clin Pharmacol*. 2011;6(3):199-206.
68. Hajj GNM, Nunes PBC, Roffe M. Genome-wide translation patterns in gliomas: an integrative view. *Cell Signal*. 2021;79:109883.

69. Ebrahimpour A, Sarfi M, Rezatabar S, Tehrani SS. Novel insights into the interaction between long non-coding RNAs and microRNAs in glioma. *Mol Cell Biochem*. 2021;476(6):2317-2335.

70. Duggan MR, Weaver M, Khalili K. PAM (PI3K/AKT/mTOR) signaling in glia: potential contributions to brain tumors in aging. *Aging*. 2021;13(1):1510-1527.

71. Colardo M, Segatto M, Di Bartolomeo S. Targeting RTK-PI3K-mTOR axis in gliomas: an update. *Int J Mol Sci*. 2021;22(9):4899.